A study has revealed four classes of antibodies that can neutralise Omicron by targeting one of four areas of the spike protein present in SARS-CoV-2 variants.
List view / Grid view
Moderna and Metagenomi have announced a collaboration to jointly create next-generation in vivo gene editing therapeutics.
Synthetic biology processes can be useful to therapeutic development, diagnostics and vaccine advancement. Drug Target Review’s Victoria Rees spoke with Dr Jim Collins, Termeer Professor of Medical Engineering & Science at MIT and Founding Core Faculty & Lead, Living Cellular Devices at the Wyss Institute at Harvard University, to explore…
A team from the University of Texas at Dallas has shown that a novel buffer solution is effective at stabilising the liposomes and lipid nanoparticles in certain COVID-19 vaccines.
Results of a recent study by researchers at the University of Bristol indicate neuropilin-1 is an important host factor for SARS-CoV-2 infection. The team suggests that blocking neuropilin-1 may be a valuable therapeutic intervention in the treatment of COVID-19. Nikki Withers spoke to one of the study’s lead investigators, Dr…
Drug Target Review rounds up some of the latest news in COVID-19 vaccine candidate R&D.